iRhythm Technologies Inc

IRTC is building a base above the 50-day SMA in a Stage 2 environment after a prolonged downtrend. EMAs have crossed above the 50-day SMA and a recent break above the two-week range high (~$123) points to an early bullish tilt. Medium-term bias is bullish, supported by base-building structure, while short-term timing favors participation now. We recommend Buy Now, engaging on pullbacks toward the $119–120 support zone near the 50-day SMA. A failure below that zone or a decisive loss of EMAs would invalidate the bullish stance.

• ↑Q2 revenue $224.2M, +20.1% YoY (seventh straight quarter >20% growth).
• ↑Raised full‐year adj. EBITDA margin to 13–14%; Q2 adj. EBITDA $43.3M (19.3% margin).
• ↓Ongoing FDA warning letter poses delays and reputational risks.